Medicenna Therapeutics (TSE:MDNA) Shares Down 1.1% – Time to Sell?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price fell 1.1% during trading on Tuesday . The company traded as low as C$0.83 and last traded at C$0.87. 26,254 shares traded hands during mid-day trading, a decline of 77% from the average session volume of 112,271 shares. The stock had previously closed at C$0.88.

Medicenna Therapeutics Trading Down 1.1%

The company has a debt-to-equity ratio of 3.30, a current ratio of 2.68 and a quick ratio of 4.65. The firm has a fifty day simple moving average of C$0.90 and a two-hundred day simple moving average of C$1.09. The firm has a market capitalization of C$72.58 million, a P/E ratio of -5.80 and a beta of 2.87.

Medicenna Therapeutics (TSE:MDNA) last issued its earnings results on Thursday, February 12th. The company reported C($0.05) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 103.51%. On average, equities research analysts anticipate that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

Medicenna Therapeutics Company Profile

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.